Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- ACCEL Lite: The Role of Imaging in Cardiovascular PreventionIn this interview, Drs. Alison L. Bailey and David J. Maron discuss “The Role of Imaging in Cardiovascular Preventionâ€.
- Characterizing Catheter Ablation For AFib in Patients With HF | NCDR Registry DataA substantial fraction of patients undergoing catheter ablation (CA) for atrial fibrillation (AFib) had heart failure (HF), with this subset experiencing higher complication rates, and those with heart failure with reduced ejection fraction (HFrEF) undergoing more adjunctive ablation...
- ACC CardiaCast: Courtside With The Chair: CV Care of the Masters Athlete – Part 1In this episode, Dr. Jonathan H. Kim is joined by Drs. Eugene H. Chung, Ankit B. Shah, and Jeffrey J. Hsu to discuss the cardiovascular care of the masters athlete.
- ACC Featured Jobs For September 2025Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!
- The 4D-ACS Trial: Ultrashort Duration of DAPT Followed by Reduced-Dose Prasugrel Monotherapy in Acute Coronary SyndromeThe 4D-ACS (The effect of DAPT [dual antiplatelet therapy] in Dosage and Duration on cardiovascular events and bleeding after implantation of DCS [drug coated stent] in ACS patients) trial was a multicenter, randomized, open-label, noninferiority study (noninferiority margin 2%; one-sided α = 0.025) that compared two antiplatelet strategies in patients with either acute coronary syndrome […]